Companies partner to perform trials of antimicrobial topical treatmentJanuary 9, 2019Stonehaven Incubate and antimicrobial protein specialist Lysando have agreed to jointly conduct proof-of-concept trials for new topical treatments based on Artilysin, a new antimicrobial platform technology.
SPONSORED CONTENTOne dose protects for 12 months.One ProHeart® 12 (moxidectin) injection puts compliance in your control. + Get started
FDA to study reducing use of dogs in trialsNovember 22, 2018The U.S. Food and Drug Administration (FDA) is proposing a study to help establish a non-animal based model to potentially replace the need to use dogs in future trials with new informatics tools.
